TrialClinical pharmacokinetics2024

Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation.

Francois Pierre Combes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.